Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
The objective of the study is to assess the safety, tolerability and pharmacokinetics of HR011408 at two formulations in healthy subject.
Official title: A Single Center, Randomized, Double-Blind, Single Ascending Dose, Crossover Designed Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
62
Start Date
2021-11-26
Completion Date
2022-01-22
Last Updated
2026-05-22
Healthy Volunteers
Yes
Conditions
Interventions
HR011408 injection
Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
Locations (1)
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China